



Stronger Together:
*EGFR Resisters' Patient
and Caregiver Summit*

Effective Communication Throughout the Cancer Care Experience

EGFR Patient & Caregiver Summit – Session 2

Recording Notice

Please be advised that this session and all general sessions of the *EGFR Resisters' Patient & Caregiver Summit* are being livestreamed and recorded.

Recordings will be made available on the EGFR Resisters website and accessible to the public.

By participating in this event, you consent to the recording and distribution of these sessions.

If you have any concerns, please speak with event staff.

Session Objectives

- Discuss the importance of patient and caregiver collaboration and relationship-building with members of the lung cancer care team, highlighting real-world experiences and benefits.
- Identify opportunities and practical strategies to effectively and equitably empower patients and caregivers in *EGFRm* lung cancer treatment decision-making.
- Apply the latest data from the evolving *EGFRm* lung cancer therapeutic landscape to individual patient scenarios, personalizing and tailoring care pathways to meet unique patient and caregiver needs.

Session Speakers

Victoria Sherry, DNP, CRNP, ANP-BC, AOCNP

Adult Oncology NP for Thoracic Malignancies
Advanced Senior Lecturer
University of Pennsylvania
Philadelphia, PA

Laura Petrillo, MD

Assistant Professor of Medicine
Palliative Care Physician
Harvard Medical School and
Massachusetts General Hospital
Boston, MA

Christine M. Lovly, MD, PhD, FASCO

Thoracic Medical Oncology
Currently transitioning between positions
Vanderbilt University Medical Center in
Nashville, TN to
City of Hope Comprehensive Cancer Center in
Duarte, CA

Beth Isaacs, BS, BSN, MPH

Patient Advocate
Chicago, IL

Patrick McGann

Caregiver
Acworth, GA



Stronger Together:
*EGFR Resisters' Patient
and Caregiver Summit*

Panel Discussion

Key Themes, Questions, and Insights from Real-World Experiences

Experiences of communication about lung cancer with a mutation

Oncologist quotes

When you find out about the mutation you get excited and try and spin it that they will live longer, you have these convenient pills to give them.

I think we, without thinking about it, almost say, "Great. You have EGFR. Great. You have ALK."... And almost, I guess, **some of us may downplay some of the side effects** because you're thinking about it in terms of chemo.

We would have patients newly diagnosed with lung cancer, and we would be like, "Yes! This is so great! I mean, you have ALK-positive lung cancer." And I think that has been something that I've struggled with more recently.. **This is a very serious illness.**

Patient quotes

To me, it's literally all just, "Blah, blah, blah." I said, "Oh, EGFR." I'd never heard what that was... so I said, "Okay, I guess that's good news." ... **It was almost like they were congratulating me.**

She said that my type of cancer was one of the most treatable ones, so **I was fortunate to have that kind of cancer** if you could call yourself fortunate to have anything like this.

They explained to me that **this is not a death sentence.** This is a long-term managed disease, and there is medication and treatments out there.

Petrillo L, et al. *Cancer*. 2022.



Stronger Together:
*EGFR Resisters' Patient
and Caregiver Summit*

Q & A

EGFR Patient & Caregiver Summit – Session 2